Gilead Sciences Yönetim

Yönetim kriter kontrolleri 2/4

Gilead Sciences CEO'su Dan O'Day, Mar2019 tarihinde atandı, in görev süresi 7.25 yıldır. in toplam yıllık tazminatı $ 28.44M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.3% maaş ve 93.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.05% ine doğrudan sahiptir ve bu hisseler ARS 114.93B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.1 yıl ve 6.4 yıldır.

Anahtar bilgiler

Dan O'Day

İcra Kurulu Başkanı

US$28.4m

Toplam tazminat

CEO maaş yüzdesi	6.31%
CEO görev süresi	7.3yrs
CEO sahipliği	0.05%
Yönetim ortalama görev süresi	6.1yrs
Yönetim Kurulu ortalama görev süresi	6.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Dan O'Day'un ücretlendirmesi Gilead Sciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	US$9b
Dec 31 2025	US$28m	US$2m	US$9b
Sep 30 2025	n/a	n/a	US$8b
Jun 30 2025	n/a	n/a	US$6b
Mar 31 2025	n/a	n/a	US$6b
Dec 31 2024	US$24m	US$2m	US$480m
Sep 30 2024	n/a	n/a	US$126m
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$485m
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$5b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$4b
Mar 31 2022	n/a	n/a	US$5b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$5b
Mar 31 2021	n/a	n/a	US$301m
Dec 31 2020	US$19m	US$2m	US$123m
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	-US$257m
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$29m	US$1m	US$5b

Tazminat ve Piyasa: Dan 'nin toplam tazminatı ($USD 28.44M ), AR pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.00M ).

Tazminat ve Kazançlar: Dan 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Dan O'Day (61 yo)

7.3yrs

Görev süresi

US$28,437,198

Tazminat

Mr. Daniel P. O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel P. O'Day	Chairman & CEO	7.3yrs	US$28.44m	0.050% ARS 114.9b
Andrew Dickinson	Executive VP & CFO	6.6yrs	US$8.77m	0.014% ARS 32.2b
Johanna Mercier	Chief Commercial & Corporate Affairs Officer	6.9yrs	US$9.30m	0.010% ARS 23.4b
Dietmar Berger	Chief Medical Officer	1.4yrs	US$13.92m	0.0015% ARS 3.5b
Erin Burkhart	Senior VP	less than a year	Veri yok	Veri yok
Jacquie Ross	Senior Vice President of Treasury & Investor Relations	5.4yrs	Veri yok	Veri yok
Keeley M. Wettan	Executive VP	less than a year	Veri yok	0.00041% ARS 947.4m
Jyoti Mehra	Executive Vice President of Human Resources	6.8yrs	Veri yok	Veri yok
Linda Higgins	Senior Vice President of Research	6.3yrs	Veri yok	Veri yok
Flavius Martin	Executive Vice President of Research	5.2yrs	Veri yok	Veri yok
Janet Dorling	Senior Vice President of Intercontinental Region & Global Patient Solutions	6.1yrs	Veri yok	Veri yok
Bernard Fine	VP of Oncology & Franchise Head of Early Development	no data	Veri yok	Veri yok

6.1yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: GILD 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel P. O'Day	Chairman & CEO	7.3yrs	US$28.44m	0.050% ARS 114.9b
Anthony Welters	Lead Independent Director	5.7yrs	US$479.96k	0.0010% ARS 2.4b
Ted Love	Independent Director	2.3yrs	US$409.92k	0.00044% ARS 1.0b
Jacqueline Barton	Independent Director	8.4yrs	US$429.92k	0.0022% ARS 5.1b
Harish Manwani	Independent Director	8.1yrs	US$432.44k	0.0012% ARS 2.8b
Jeffrey Bluestone	Independent Director	5.5yrs	US$409.78k	0.00081% ARS 1.9b
Kelly Kramer	Independent Director	9.8yrs	US$437.44k	0.00011% ARS 254.2m
Javier Rodriguez	Independent Director	6yrs	US$409.92k	0.0011% ARS 2.5b
Sandra Horning	Independent Director	6.4yrs	US$433.94k	0.00051% ARS 1.2b

6.4yrs

Ortalama Görev Süresi

71yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GILD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/05 19:26
Gün Sonu Hisse Fiyatı	2026/06/05 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Gilead Sciences, Inc. 65 Bu analistlerden 24, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Toung	Argus Research Company
Brian Skorney	Baird
Emily Field	Barclays

Gilead Sciences Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Gilead Sciences, Inc., Annual General Meeting, Apr 30, 2026

Gilead Sciences, Inc. Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Effective December 18, 2025

Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025

Gilead Sciences, Inc., Annual General Meeting, May 07, 2025

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

Recent updates

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of Ouro Medicines, Inc. from Keymed Biosciences Inc. (SEHK:2162) and others.

Gilead Sciences Announces Statistically Significant Composite ALP Normalization With Livdelzi In Phase 3 IDEAL Trial In Primary Biliary Cholangitis

Gilead Sciences Shares Interim Phase 3 ASSURE Data Demonstrating High And Sustained ALP Normalization With Livdelzi (Seladelpar) In People With Primary Biliary Cholangitis

Gilead Sciences, Inc. Receives U.S. FDA Priority Review For Once-Daily HIV Treatment Bictegravir Plus Lenacapavir

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of 77.2% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others.

Gilead Sciences, Inc. to Report Q1, 2026 Results on May 07, 2026

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion.

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Ouro Medicines, Inc. from Keymed Biosciences Inc. (SEHK:2162) and others for $2.2 billion.

Gilead Sciences, Inc., Annual General Meeting, Apr 30, 2026

Gilead Sciences, Inc. Announces the Presentation of New Phase 3 ARTISTRY-1 and ARTISTRY-2 Trial Data At CROI 2026

Gilead Sciences, Inc. to Present New Hiv Treatment and Prevention Data At Croi 2026, with A Focus on Expanding Options

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2026

Fda Approves Label Update for Kite's Yescarta®? for Relapsed/Refractory Primary Central Nervous System Lymphoma

Gilead Sciences, Inc. to Report Q4, 2025 Results on Feb 10, 2026

Gilead Sciences, Inc. Announces New England Journal of Medicine Publishes Phase 3 ASCENT-04/KeyNOTE-D19 Results Supporting Trodelvy®? Plus Keytruda®? as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-Negative Breast Cancer

Gilead Sciences, Inc. Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Effective December 18, 2025

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ARTISTRY-2 Trial

Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025

Gilead Sciences, Inc. Joins Partners for Delivery of First Shipments of Breakthrough Twice-Yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Gilead Sciences, Inc.'s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ART-1 Trial

Gilead Sciences, Inc. Provides Update on Phase 3 ASCENT-07 Study

Gilead Sciences, Inc. announces Quarterly dividend, payable on December 30, 2025

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2025

Gilead Sciences, Inc. to Showcase Interim Long-Term Efficacy Data for Livdelzi (Seladelpar) in Primary Biliary Cholangitis (Pbc) and Investigational Bulevirtide in Chronic Hepatitis Delta

Gilead Sciences, Inc. Receives Health Canada Approval for the Treatment of Primary Biliary Cholangitis

Gilead Sciences, Inc. to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

Gilead Presents New Hiv Research Data At EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care with New Data At Esmo 2025

Gilead Sciences, Inc. to Report Q3, 2025 Results on Oct 30, 2025

Gilead Sciences, Inc. Announces European Commission Authorizes Twice-Y Early Yeytuo (Lenacapavir) for HIV Prevention

Gilead Sciences, Inc. (NasdaqGS:GILD) announces an Equity Buyback for $6,000 million worth of its shares.

Gilead Receives Positive CHMP Opinions Under Accelerated Review from European Medicines Agency for Twice-Yearly HIV PrEP Option in the European Union

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention At Ias 2025

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approves Yeztugo (Lanacapavir) as Pre-Exposure Prophylaxis

Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-03 Study of Trodelvy

Gilead's Livdelzi (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented At EASL 2025

Gilead Sciences, Inc. to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Gilead Sciences, Inc. Declares Quarterly Dividend for the Second Quarter of 2025, Payable on June 27, 2025

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ASCENT-04/KeyNOTE-D19 Study

Gilead Sciences, Inc. to Report Q1, 2025 Results on Apr 24, 2025

Gilead Sciences, Inc., Annual General Meeting, May 07, 2025

Gilead Sciences, Inc. Presents New HIV Treatment and Cure Research Data At CROI 2025, Including an Investigational Long-Acting, Twice-Y Early Therapy Option

European Medicines Agency Validates Gilead's Marketing Authorization Application and Eu-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv Prevention

Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

Gilead Sciences, Inc. Announces U.S. FDA Acceptance of Its New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2025

Gilead Sciences, Inc. to Report Q4, 2024 Results on Feb 11, 2025

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Kite, Gilead Company, Announces Results from Four Analyses That Continue to Demonstrate Durability of Response of Tecartus in Patients with R/R MCL and R/R B-ALL During 66th ASH Annual Meeting and Exposition

Gilead Sciences, Inc.' Company Kite Presents New Data Underscoring Curative Potential of Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH

Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results

Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program